FOMX News and Press, Foamix Pharmaceuticals Ltd. From 08/07/19

Foamix Pharmaceuticals (NASDAQ: FOMX ): Q2 GAAP EPS of -$0.35 beats by $0.02 . More news on: Foamix Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

REHOVOT, Israel, and BRIDGEWATER, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical thera...

REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announc...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...

Sigma Labs (NASDAQ: SGLB ) +19%  to work with airbus to deploy PrintRite3D rapid test and evaluation program More news on: Sigma Labs, Inc., Valeritas Holdings, Inc., RingCentral, Inc., Stocks on the move, Read more ...

Thinly traded micro cap Foamix Pharmaceuticals (NASDAQ: FOMX ) is up  11%  premarket on modest volume in reaction to its announcement that it has secured up to $64M in new capital. More news on: Foamix Pharmaceuticals Ltd., Healthcare stocks news, Stocks on the move, Read m...

Foamix secures up to $50 million in non-dilutive funding Company secures $14 million via a registered direct offering of equity REHOVOT, Israel and BRIDGEWATER, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinica...

REHOVOT, Israel, and BRIDGEWATER, N.J., July 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditi...

2019 has been a busy year for Foamix Pharmaceuticals ( FOMX ) but the second half of this year will be even busier with several major events. The company has a PDUFA date on October 20 for its most advanced candidate FMX101 for acne. If approved, FMX101 would be the company’s first co...

REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announc...